Nicox: 2021 Ordinary and Extraordinary General Meetings postponed to April 28, 2021

Press ReleaseNicox: 2021 Ordinary and Extraordinary General Meetings postponed to April 28, 2021  April 13, 2021 Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, informs its shareholders that the ordinary general meeting and the extraordinary general meeting convened on first call on Wednesday April 14, 2021, as closed meetings, without the physical presence of the shareholders, cannot be held as the quorum required by law will not be reached. The shareholders of Nicox are thus convened on second call for an ordinary general meeting followed by an extraordinary general meeting on the same resolutions and the same agenda on Wednesday April 28, 2021 at 2:00 pm CET, as closed meetings, without the physical presence of the shareholders. The documents mentioned in articles R.22-10-23 of the French Code de commerce, including those to be presented at the general meetings, are available on the Company’s website www.nicox.com. The ordinary general meeting and the extraordinary general meeting of April 14, 2021 acknowledging the lack of quorum, will be broadcasted live and recorded in audio format on Nicox’s website www.nicox.com. The Chief Executive Officer of Nicox, upon delegation by the Board of Directors on February 26, 2021, appointed Ms. Brigitte Duquesroix and Ms. Irène Lalande as scrutineers. Shareholders may vote at the general meetings of April 28, 2021 ahead of these meetings by correspondence or by proxy, by post or electronically. All the information relating to the voting process can be found on the Company’s website. Shareholders may also contact the Investor Relations team at [email protected] for any question on the voting process. The proxy forms sent by correspondence or the electronic votes for the general meetings of April 14, 2021 remain valid for the general meetings of April 28, 2021.About NicoxNicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health.  Nicox’s lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with glaucoma.  The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis.  Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of South East Asian markets.  Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. For more information on Nicox, its products or pipeline, please visit: www.nicox.com.Analyst coverage  Bryan, Garnier & Co                Victor Floc’h                Paris, FranceCantor Fitzgerald                    Louise Chen                New York, U.S.Edison Investment Research Pooya Hemami            London, UKH.C. Wainwright & Co             Yi Chen                        New York, U.S.Kepler Cheuvreux                    Damien Choplain        Paris, France   The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current.  Nicox disavows any obligation to correct or to update the information contained in analyst reports.ContactsNicoxGavin SpencerExecutive Vice President, Chief Business Officer& Head of Corporate Development  T +33 (0)4 97 24 53 [email protected] Investors & MediaUnited States & Europe LifeSci Advisors, LLC Mary-Ann Chang T +44 7483 284 [email protected] Advisors, LLCSophie BaumontM +33 (0)6 27 74 74 49 [email protected] StatementsThe information contained in this document may be modified without prior notice.  This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance.  These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.  Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements. Risks factors which are likely to have a material effect on Nicox’s business are presented in the 3rd chapter of the ‘Document d’enregistrement universel, rapport financier annuel et rapport de gestion 2020’ filed with the French Autorité des Marchés Financiers (AMF) on March 1, 2021 which are available on Nicox’s website (www.nicox.com).Nicox S.A.Drakkar 2 Bât D, 2405 route des Dolines CS 10313, Sophia Antipolis 06560 Valbonne, France T +33 (0)4 97 24 53 00 F +33 (0)4 97 24 53 99  
Attachment

EN_AG 2021 – lack quorum_ 202104016_F